1. Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation.
- Author
-
Woo MS, Ufer F, Rothammer N, Di Liberto G, Binkle L, Haferkamp U, Sonner JK, Engler JB, Hornig S, Bauer S, Wagner I, Egervari K, Raber J, Duvoisin RM, Pless O, Merkler D, and Friese MA
- Subjects
- Animals, Cell Survival genetics, Cells, Cultured, Central Nervous System pathology, Encephalomyelitis, Autoimmune, Experimental genetics, Encephalomyelitis, Autoimmune, Experimental metabolism, Gene Expression Profiling methods, Gene Regulatory Networks genetics, Humans, Inflammation metabolism, Mice, Inbred C57BL, Mice, Knockout, Multiple Sclerosis genetics, Multiple Sclerosis metabolism, Neurodegenerative Diseases metabolism, Neurons cytology, Neurons metabolism, Neuroprotective Agents metabolism, Receptors, Metabotropic Glutamate metabolism, Signal Transduction genetics, Mice, Central Nervous System metabolism, Inflammation genetics, Neurodegenerative Diseases genetics, Receptors, Metabotropic Glutamate genetics
- Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with continuous neuronal loss. Treatment of clinical progression remains challenging due to lack of insights into inflammation-induced neurodegenerative pathways. Here, we show that an imbalance in the neuronal receptor interactome is driving glutamate excitotoxicity in neurons of MS patients and identify the MS risk-associated metabotropic glutamate receptor 8 (GRM8) as a decisive modulator. Mechanistically, GRM8 activation counteracted neuronal cAMP accumulation, thereby directly desensitizing the inositol 1,4,5-trisphosphate receptor (IP3R). This profoundly limited glutamate-induced calcium release from the endoplasmic reticulum and subsequent cell death. Notably, we found Grm8-deficient neurons to be more prone to glutamate excitotoxicity, whereas pharmacological activation of GRM8 augmented neuroprotection in mouse and human neurons as well as in a preclinical mouse model of MS. Thus, we demonstrate that GRM8 conveys neuronal resilience to CNS inflammation and is a promising neuroprotective target with broad therapeutic implications., Competing Interests: Disclosures: M.A. Friese reported personal fees from Novartis, personal fees from Roche, personal fees from Merck EMD, and personal fees from Biogen outside the submitted work. No other disclosures were reported., (© 2021 Woo et al.)
- Published
- 2021
- Full Text
- View/download PDF